Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

In this study (n=318), triple therapy (metformin, pioglitazone, and exenatide) in newly diagnosed type 2 diabetes was associated with a 0.50% (95% CI 0.39–0.61; P<0.0001) larger decrease in HbA1c at 3 years than conventional therapy (metformin followed by glipizide and insulin).

Diabetes Care